{"schema":"sb.node.v1","id":"sb:e/fdf7c16b5fed002f8364d62c","kind":"entity","label":{"text":"her2","locale":"en"},"identity":{"anchor":"label:en:her2","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T13:13:12.220585+00:00","snapshot":"deploy 0179e3ac7995bc9e92bae3a80f173732f24a5d75"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":131,"separatePublishers":34,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":1,"named":11,"of":11,"basis":"receipts the entity graph keeps whose own headline names the subject, over all receipts it keeps for the subject (the door's measurement; the graph carries none of its own). Only the former are served"}},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-03-22","to":"2026-10-07","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.298: about 70% of mentions carry no typed assertion"]}},"dimensions":{"domains":["precision_medicine","society_news","oncology"],"activeDays":52,"assertions":{"regulatory-approval":29,"election":3,"acquisition":2,"launch-release":2,"utterance":1,"funding-round":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/4f1b952444d497d63698fac9","kind":"observation","label":"Latest News · 2026-10-07 · OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma | OSTX Stock News","url":"https://www.stocktitan.net/news/OSTX/os-animal-health-receives-usda-feedback-on-regulatory-pathway-for-1go9fqd8ws4d.html"},{"id":"sb:o/6164cd5c9362b09700f9ad34","kind":"observation","label":"medRxiv Oncology · 2026-10-07 · Multimodal Artificial Intelligence Predicts Pathological Response and Prognosis in HER2-Positive Early Breast Cancer Treated with Chemotherapy De-escalation Strategies…","url":"https://www.medrxiv.org/content/10.64898/2026.10.05.26364736v1?rss=1"},{"id":"sb:o/6118c418b7e4dab053c5be12","kind":"observation","label":"FDA · 2026-10-07 · FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer","url":"http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer"},{"id":"sb:o/029b3d60d0ceab7c4d7a4e88","kind":"observation","label":"Frontiers Precision Oncology · 2026-10-06 · Integrated CDK4/6 inhibitor resistance and primary-metastatic discordance in hormone receptor-positive/HER2-negative metastatic breast cancer: a translatio…","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1918231"},{"id":"sb:o/fba1cf976652af9d9b3c965c","kind":"observation","label":"Frontiers Precision Oncology · 2026-09-25 · Small cell transformation during acquired resistance to zongertinib in HER2-mutant non-small cell lung cancer: a case report","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1934878"},{"id":"sb:o/519d9a8a2891f95f40ad3c3a","kind":"observation","label":"Frontiers Precision Oncology · 2026-09-25 · Individualized treatment of HER2-positive breast cancer patients with lung metastasis using a circulating tumor cell drug sensitivity test: a case report","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1888730"},{"id":"sb:o/7b4420de354371e64514b2b9","kind":"observation","label":"Frontiers Precision Oncology · 2026-09-23 · HER2 amplification as a resistance mechanism to osimertinib and its successful treatment with trastuzumab deruxtecan: a case report","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1921556"},{"id":"sb:o/098b843e301c3ec077063e95","kind":"observation","label":"Nature Medicine · 2026-09-22 · Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial","url":"https://www.nature.com/articles/s41591-026-04679-x"},{"id":"sb:o/fd54375928c464aee95c5da4","kind":"observation","label":"The ASCO Post · 2026-09-22 · Metastatic HER2-Mutant NSCLC First-Line T-DXd","url":"https://ascopost.com/videos/iaslc-wclc-2026/metastatic-her2-mutant-nsclc-first-line-t-dxd/"},{"id":"sb:o/2afb6d9c62c7d353e3ade5bb","kind":"observation","label":"Front Pharmacol · 2026-09-21 · Case Report: zanidatamab-based regimen as a potential later-line therapeutic option in HER2-amplified metastatic colorectal cancer.","url":"https://doi.org/10.3389/fphar.2026.1925069"}],"cursor":"c1.eyJpZCI6InNiOmUvZmRmN2MxNmI1ZmVkMDAyZjgzNjRkNjJjIiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTEwVDEzOjEzOjEyLjIyMDU4NSswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity whose own headline names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":{"state":"cannot-measure","reason":"claims: this subject's maintained record could not be read (the maintained record \"her2\" could not measure its claims: this subject was retired from the publication registry on 2026-09-30 (no longer clears the admission conditions — re-checked 2026-09-30 (no receipt in the corpus-evidence shard for this label)); the record is kept as a dated tombstone and is no longer maintained). The items listed come from the passes that could be read"},"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with breast cancer (71 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/0000a9d810182f4106c351f3"},{"kind":"relation","label":"co-mentioned with fda (47 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9b86392861a7f61ade573ad8"},{"kind":"relation","label":"co-mentioned with her2-negative (44 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/5ffcb60758915053566fb54f"},{"kind":"relation","label":"co-mentioned with colorectal cancer (43 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/55abb893255f2b4da5ed990d"},{"kind":"relation","label":"co-mentioned with immunotherapy (40 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/5c2dd7d46437a9e695870381"},{"kind":"relation","label":"co-mentioned with her2-positive (39 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d453bb0dbf62bdcf3d1b5abf"},{"kind":"relation","label":"co-mentioned with studie (38 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c0fc38cdc0a75bd811b6ac64"},{"kind":"relation","label":"co-mentioned with egfr (35 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3acc259d344f5d4b5d3211f9"},{"kind":"relation","label":"co-mentioned with lung cancer (33 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/7731e0056186ce15d4ce55f7"},{"kind":"relation","label":"co-mentioned with her2-directed (24 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c6e941205c73557467cc7d79"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/fdf7c16b5fed002f8364d62c","mcp":"traverse {\"id\":\"sb:e/fdf7c16b5fed002f8364d62c\"}","page":"/entity/her2/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/fdf7c16b5fed002f8364d62c\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/fdf7c16b5fed002f8364d62c\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/fdf7c16b5fed002f8364d62c\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/fdf7c16b5fed002f8364d62c\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}